These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31782067)

  • 1. The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A.
    Napolitano M; Nøhr AM
    Drugs R D; 2019 Dec; 19(4):381-390. PubMed ID: 31782067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C.
    Napolitano M; Olsen AA; Nøhr AM; Eichler H
    J Blood Med; 2021; 12():9-20. PubMed ID: 33536803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro.
    Takeyama M; Nøhr AM; Pollard D
    TH Open; 2020 Oct; 4(4):e354-e361. PubMed ID: 33195971
    [No Abstract]   [Full Text] [Related]  

  • 4. Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A.
    Takedani H; Hirose J
    Drug Des Devel Ther; 2015; 9():1767-72. PubMed ID: 25848213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
    Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
    J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative analysis of heterogeneity in commercially available recombinant factor VIII products.
    Baunsgaard D; Nielsen AD; Nielsen PF; Henriksen A; Kristensen AK; Bagger HW; Ezban M
    Haemophilia; 2018 Nov; 24(6):880-887. PubMed ID: 29726070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Turoctocog alfa for the treatment of hemophilia a.
    Vakil NH; Fujinami N; Martin-Stone S
    Pharmacotherapy; 2014 Oct; 34(10):1091-101. PubMed ID: 25052207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
    Kulkarni R; Karim FA; Glamocanin S; Janic D; Vdovin V; Ozelo M; Rageliene L; Carboni E; Laguna P; Dobaczewski G; Seremetis S; Lindblom A; Santagostino E
    Haemophilia; 2013 Sep; 19(5):698-705. PubMed ID: 23651313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials.
    Tosetto A; Neff A; Lentz SR; Santagostino E; Nemes L; Sathar J; Meijer K; Chowdary P; Shen C; Landorph A; Hampton K
    Haemophilia; 2020 May; 26(3):450-458. PubMed ID: 32293786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP.
    Pickering W; Hansen M; Kjalke M; Ezban M
    J Thromb Haemost; 2016 Aug; 14(8):1579-87. PubMed ID: 27241682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study.
    Escuriola Ettingshausen C; Katsarou O; Kotnik BF; Borel Derlon A; Schwarz R; Ypma PF; Matytsina I; Dey S; Schutgens REG
    Haemophilia; 2022 Jan; 28(1):46-54. PubMed ID: 34791736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Turoctocog alfa for the treatment of hemophilia A.
    Haddley K
    Drugs Today (Barc); 2014 Feb; 50(2):121-31. PubMed ID: 24619589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
    Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
    Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of the safety and efficacy of turoctocog alfa for hemophilia A.
    Boban A; Hermans C
    Expert Rev Hematol; 2020 Apr; 13(4):303-311. PubMed ID: 32153219
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of turoctocog alfa in patients with hemophilia A requiring surgical procedures: A multicentre retrospective study.
    Drillaud N; Cussac V; Bertho PO; Horvais V; Beurrier P; Ternisien C; Rose J; Fouassier M; Babuty A; Trossaërt M
    Transfusion; 2023 Dec; 63(12):2321-2327. PubMed ID: 37850587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability and sterility of a recombinant factor VIII concentrate prepared for continuous infusion administration.
    Belgaumi AF; Patrick CC; Deitcher SR
    Am J Hematol; 1999 Sep; 62(1):13-8. PubMed ID: 10467271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new recombinant factor VIII: from genetics to clinical use.
    Santagostino E
    Drug Des Devel Ther; 2014; 8():2507-15. PubMed ID: 25548513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
    Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
    Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials.
    Santagostino E; Lentz SR; Misgav M; Brand B; Chowdary P; Savic A; Kilinc Y; Amit Y; Amendola A; Solimeno LP; Saugstrup T; Matytsina I
    Haemophilia; 2015 Jan; 21(1):34-40. PubMed ID: 25273984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.
    Ezban M; Vad K; Kjalke M
    Eur J Haematol; 2014 Nov; 93(5):369-76. PubMed ID: 24797664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.